ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
← catalyst calendarNCT07007559 · readout ≤ 499 d
Sponsored by ALX Oncology Inc. (industry) · ALXO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120estimated
Sites
54
Countries
Canada, France, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-10 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer, Metastatic
Interventions
- Drug: Evorpacept (ALX148)
- Drug: Trastuzumab — also filed as Herceptin
- Drug: Paclitaxel — also filed as Taxol
- Drug: Capecitabine — also filed as Xeloda
- Drug: Eribulin — also filed as Halaven
- Drug: Gemcitabine — also filed as Gemzar
- Drug: Vinorelbine — also filed as Navelbine
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR) using RECIST v1.1 based on BICR assessment
measured Approximately 6 months after the last participant is enrolled
Permalink · ALXO's whole pipeline · Catalyst calendar · Every registered study · What changed